For donors and investors, vaccines are also one of the best buys in health. Each US$ 1 of investment in immunisation will give a return of $21 dollars, rising to $54 when broader societal benefits are included.
Vaccines do far more than protect health; they also prevent loss of income due to health issues and promote productivity and economic growth.
Education and nutrition: Immunised children are more likely to be well nourished, perform better at school and grow up to become productive adults.
Health and productivity. Children who are vaccinated are protected from many childhood diseases; they get less sick, less often. As a result, their parents and carers spend less time nursing them through sickness. This has direct benefits in terms of ability to work inside and outside the home.
Poverty: People who work more are able to contribute more to household incomes. Less time spent caring for sick children means as much as $1 billion more available over a decade for families in low and middle income countries to spend or save. Vaccines administered from 2016-2030 will help prevent 24 million people in many of the world’s poorest countries from slipping into poverty.
Families and communities: As fewer people have to look after sick children and more are able to work, communities can do better economically, increasing spending and savings rates and contributing to greater national economic growth. Over the current decade, lower care costs for health systems and for families could save up to $6 billion in treatment costs.
Gender equity: While girls and boys have equal access to vaccination globally, gender barriers face by their mothers or caregivers affect their chances of being immunised. A gender-focused approach to vaccination programmes will further ensure that men and women become active agents in their children's immunisation.
Climate: Immunisation mitigates the risk of outbreaks of diseases tied to climate change, such as yellow fever and cholera—especially in urban and post-disaster settings and makes communities more resilient to its effects.
IFFIm provides a smart solution to one of the main constraints facing immunisation efforts: a shortage of large-scale, long-term funding that is stable, predictable and coordinated. Extending immunisation coverage in the world requires long-term planning and funding for projects such as health worker training, and creating predictable markets for vaccines.
IFFIm’s frontloading development assistance invests the majority of money “up front” allowing both developing countries and vaccine manufacturers to plan for longer periods of time knowing the necessary resources will be available. This predictability increases efficiency, planning and results.